TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07374471: A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Mage Biologics · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,926,600

Rescue Site Savings

+$3,255,075

Unlock Full NCT07374471 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07374471 Rescue Dossier →